Related Experiment Video

Updated: Jul 6, 2025

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology
07:04

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Published on: May 2, 2025

326

Immune-Checkpoint Inhibitors: A New Line of Attack in Triple-Negative Breast Cancer

Ouissam Al Jarroudi1,2, Khalid El Bairi3,4, Giuseppe Curigliano5,6

  • 1Faculty of Medicine and Pharmacy, Mohammed Ist University, Oujda, Morocco. aljarroudi.ouissam@gmail.com.

Cancer Treatment and Research
|January 4, 2024
PubMed

Insights

Triple-negative breast cancer (TNBC) has a poor prognosis, but immune checkpoint inhibitors (ICIs) targeting programmed cell death protein-1 (PD-1) show promise. This review discusses ICIs for all stages of TNBC treatment.

Area of Science:

  • Oncology
  • Immunotherapy

Background:

  • Triple-negative breast cancer (TNBC) presents a significant clinical challenge due to its poor prognosis and limited treatment options.
  • Chemotherapy has been the primary treatment modality for TNBC.
  • Emerging immunotherapies, specifically immune checkpoint inhibitors (ICIs), are transforming TNBC treatment paradigms.

Purpose of the Study:

  • To provide a comprehensive overview of immune checkpoint inhibitors (ICIs) utilized in the treatment of triple-negative breast cancer (TNBC).
  • To discuss the current applications and ongoing investigations of ICIs across various stages of TNBC.

Main Methods:

  • Review of clinical trials and approved indications for ICIs in TNBC.
  • Analysis of neoadjuvant and adjuvant treatment strategies involving ICIs.
  • Discussion of programmed cell death protein-1 (PD-1) targeted therapies.

Main Results:

  • Immune checkpoint inhibitors (ICIs), particularly those targeting programmed cell death protein-1 (PD-1), have been approved in combination with chemotherapy for first-line treatment of PD-1 expressing TNBC.
  • ICIs are under active investigation in both neoadjuvant and adjuvant settings for TNBC patients.
  • These advancements offer new therapeutic avenues for improving outcomes in TNBC.

Conclusions:

  • Immune checkpoint inhibitors represent a significant advancement in the management of triple-negative breast cancer.
  • The role of ICIs is expanding across all stages of TNBC, offering improved therapeutic options.
  • Further research will continue to refine the use of ICIs in TNBC treatment protocols.
Keywords:
BiomarkersClinical trialsImmune-checkpoint inhibitorsTriple-negative breast cancer

More Related Videos

Studying Triple Negative Breast Cancer Using Orthotopic Breast Cancer Model09:29

Studying Triple Negative Breast Cancer Using Orthotopic Breast Cancer Model

Published on: March 20, 2020

17.7K
Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood06:07

Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood

Published on: February 5, 2020

5.8K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.6K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.8K
Negative Regulator Molecules01:23

Negative Regulator Molecules

Positive regulators allow a cell to advance through cell cycle checkpoints. Negative regulators have an equally important role as they terminate a cell’s progression through the cell cycle—or pause it—until the cell meets specific criteria.
35.4K
The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
6.6K
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
529
Cancer-Critical Genes II: Tumor Suppressor Genes01:05

Cancer-Critical Genes II: Tumor Suppressor Genes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
7.4K